It doesn't get much more "what you see is what you get" than The Inkey List. This brand actually names each of its products for the hero inside, so there's literally no question what the active ingredient is when reading Retinol Eye Cream, Kaolin Mask, or Lactic Acid Serum off a label.

In addition to eliminating confusion with straightforward products, the brand also has a 24/7, 365-days-a-year customer-service program with free, personalized skin-care advice. If that wasn't tempting enough, every single item is under $15, and many are found right at Sephora.

We looked through its bestselling, top-rated products and picked out the ones we'd add to our own lists. Find our favorite toners, serums, cleansers, and more from The Inkey List ahead.

A Guide to the Very Best Products From The Inkey List (and They're All Under $15)

The Inkey List Salicylic Acid Acne + Pore Cleanser

The Inkey List Salicylic Acid Acne + Pore Cleanser ($10) lightly cleanses skin while acne-fighting ingredients like salicylic acid and zinc help heal and reduce blemishes and blackheads.

The Inkey List Polyhydroxy Acid (PHA) Gentle Exfoliating Toner

For skin that's a bit too sensitive for most toners and acids, The Inkey List Polyhydroxy Acid (PHA) Gentle Exfoliating Toner ($11) features larger PHA molecules to gently exfoliate and lock in moisture, and adds aloe leaf juice to soothe.

The Inkey List Brighten-i Eye Cream

The Inkey List Brighten-i Eye Cream ($10) illuminates the under-eye area to reduce the appearance of dark circles, and also helps fill in fine lines so concealer or foundation goes on even smoother.

The Inkey List Beta Hydroxy Acid (BHA) Blemish + Blackhead Serum

The Inkey List Beta Hydroxy Acid (BHA) Blemish + Blackhead Serum ($11) has anti-inflammatory and anti-bacterial properties to calm breakouts, while also exfoliating and reducing excess sebum in oily skin types.

The Inkey List Hyaluronic Acid Hydrating Serum

The Inkey List Hyaluronic Acid Hydrating Serum ($8) offers intense hydration with hyaluronic acid plus a peptide to support natural collagen production and plump up skin.

The Inkey List Tranexamic Acid Hyperpigmentation Treatment

The Inkey List Tranexamic Acid Hyperpigmentation Treatment ($15) takes on dark spots overnight thanks to potent brightening ingredients like tranexamic acid, aai berry, and a vitamin C derivative.

The Inkey List Peptide Moisturizer

The Inkey List Peptide Moisturizer ($15) is a deeply hydrating cream that firms skin with peptides and also supports its natural moisture barrier.

The Inkey List Rosehip Nourishing Night Oil

The Inkey List Rosehip Nourishing Night Oil ($11) takes on dull, tired complexions with 100 percent, cold-pressed rosehip oil that softens skin overnight.

The Inkey List Glycolic Acid Exfoliating Toner

The sugarcane-derived glycolic acid in The Inkey List Glycolic Acid Exfoliating Toner ($11) naturally exfoliates dead skin cells and reduces the appearance of pores, too.

The Inkey List Polyglutamic Acid Hydrating Serum

The Inkey List Polyglutamic Acid Hydrating Serum ($15) works well as a primer as it covers skin with a thin film that locks in moisture and smoothes the surface (but still lets oxygen through).

The Inkey List Vitamin B, C, and E Moisturizer

The Inkey List Vitamin B, C, and E Moisturizer ($5) is a true multitasker as it packs oil-controlling vitamin B3 (a.k.a. niacinamide) along with brightening vitamin C and nourishing vitamin E.

The Inkey List Q10 Antioxidant Serum

The Inkey List Q10 Antioxidant Serum ($7) protects skin from pollution and other environmental stressors while also hydrating with its lightweight serum formula.

The Inkey List Bakuchiol Retinol Alternative Moisturizer

The Inkey List Bakuchiol Retinol Alternative Moisturizer ($10) uses a plant-derived, antioxidant-rich alternative to retinol to take on fine lines and uneven skin tone.

The INKEY List Caffeine Eye Cream

The INKEY List Caffeine Eye Cream ($10) combats under-eye puffiness with caffeine in a lightweight, hydrating formula.

The Inkey List Collagen Booster Firming Peptide Serum

Collagen naturally plumps and firms skin and The Inkey List Collagen Booster Firming Peptide Serum ($11) mimics that same result with its peptide instead.

The Inkey List Apple Cider Vinegar Acid Peel

The Inkey List Apple Cider Vinegar Acid Peel ($15) both minimizes the appearance of scars and redness from past acne while also targeting blemish-causing bacteria moving forward.

The Inkey List Kaolin Mask

Both types of clay in The Inkey List Kaolin Mask ($7) absorb excess oil in the skin while also drawing out any impurities, dead skin cells, and dirt that may have clogged pores.

The Inkey List Alpha Arbutin Brightening Serum

The Inkey List Alpha Arbutin Brightening Serum ($12) takes on dark spots, scars, and hyperpigmentation while hydrating skin with squalane at the same time.

The Inkey List Ceramide Hydrating Night Treatment

The multi-ceramide complex in The Inkey List Ceramide Hydrating Night Treatment ($15) forms a protective layer so less moisture is lost overnight and skin is left supple and hydrated come morning.

The Inkey List Snow Mushroom Hydrating Gel Moisturizer

The Inkey List Snow Mushroom Hydrating Gel Moisturizer ($10) is lightweight gel that reduces redness and soothes skin with cooling snow mushroom.

The Inkey List Squalane Oil

For anyone nervous about trying a facial oil, The Inkey List Squalane Oil ($12) is not only non-greasy, it actually helps with oil control while also moisturizing skin.

The Inkey List Turmeric Brightening Moisturizer

The Inkey List Turmeric Brightening Moisturizer ($13) takes on redness and irritated skin with antioxidant-rich turmeric root extract and vitamin E.

The Inkey List Lactic Acid Serum

The Inkey List Lactic Acid Serum ($13) brightens and evens out a dull skin tone by gently exfoliating dead cells off the surface.

Love all things beauty? Can't get enough products? Come join our Facebook Group, Real Reviews With POPSUGAR Beauty There are lots of fun conversations happening there, as well as all the product recommendations you could ask for - not just from us, but also community members, too.

Read the original here:
A Guide to the Very Best Products From The Inkey List (and They're All Under $15) - Yahoo Lifestyle

Skin Stem Cells Comments Off on A Guide to the Very Best Products From The Inkey List (and They’re All Under $15) – Yahoo Lifestyle | June 17th, 2020

Much has changed in the last 12 months. Its a new decade and a whole new world. Even before Covid-19 obliterated normal, long-held conventions were collapsing faster than a tweetstorm. The very idea of masculinity has been rightly redrawn and recast, but theres not yet a definition we can all agree on. From this uncertainty has come not a movement, exactly, but certainly a move toward something were calling soft power. Its about gaining strength through vulnerability, bringing empathy to the fore, seeking to understand rather than impose. With the daily news dominated by sociopolitical Sturm und Drang, consideration has become commanding.

So what is style in this new world order? Strong-shouldered suits and immaculately shined oxfords, long the international uniform of success, dont quite speak the right language today. Its not that the power suit is deadmore that its current incarnation has evolved in tune with our notion of what strength is.

Its a shift that designers presaged months ago. The best new menswear traffics in a similarly soft kind of power,a more nuanced take on the trappings that have always given men an authoritative sense of style. Theyre pieces that maintain the decorum of traditional tailoring but knock the starch out of it with fluid construction, downy textiles, soothing colors. When in doubt, Brunello Cucinelli (the epitome of soft power in many ways) is there for you. So too Herms, Gabriela Hearst and newcomer Saman Amel.

After months in lockdown, we are all craving humanity, and how we present ourselves to the world has become especially meaningful. Consider Jason Momoa, the hulking he-man of Aquaman, who, at this years Golden Globes, strolled the red carpet in an emerald velvet Tom Ford dinner jacket teamed with an Art Decoinspired Cartier brooch. Very much a soft-power MVP move.

Theres a new generation who is pushing at the boundaries of menswear, and while we arent advocating for pussy- bow blouses (but rock on, Harry Styles), what can we learn from their adventures? That now, more than ever, is the time to express yourself, whether that means a scarf in a daring silk rather than your usual cashmere, or a dramatically peaked lapel to imbue a classic blue blazer with a frisson of attitude. Above any sartorial flourish, though, it will be the little thingsthe weave of a sweater, the topstitching on a shirt, that human touchthat telegraph real style savvy. Quiet luxury, stealth wealthwhatever it is you call it, it has never been less cool to be the loudest guy in the room.

Read this article:
The Best of the Best in Style for 2020 Robb Report - Robb Report

Skin Stem Cells Comments Off on The Best of the Best in Style for 2020 Robb Report – Robb Report | June 16th, 2020

Like many states, the UK government has committed to supporting disruptive innovations.1 These are considered to hold greater potential for economic growth and development than incremental advances in established technologies. Within this broad strategy the bioeconomy, the area of industrial activity based on commercialising life sciences research is given a particular importance. The bioeconomy includes sectors like biofuels, agricultural biotechnology, and medical biotechnology.2 In the latter case, advances in medical biotechnologies hold promise for treating, and even curing, serious and chronic diseases as well as driving growth and prosperity. Regenerative medicine (RM), the biotechnology-based use of cells, tissues, and genes as medicinal products, is certainly disruptive in that they differ in important ways from traditional pharmaceuticals and medical devices.3

The UK has taken a number of policy measures to support the development of the RM industry. The Regenerative Medicine Platform funding schemes promote and co-ordinate academic translational research. The Catapult centres, including the Cell and Gene Therapy Catapult, the Medicines Discovery Catapult and the High Value Manufacturing Catapult, provide advice, facilities and infrastructure to support businesses, especially Small and Medium-sized Enterprises (SMEs); with potential to contribute to the RM value chain. The Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Office offers a RM advice service to help academic and commercial developers navigate the complex regulatory framework for biological therapies, while the recent Accelerated Access Review proposed a raft of measures to speed up the regulatory timeline for transformative new therapies more generally.4

However, it does not necessarily follow that all parts of the biomedical sector will be equally disrupted by any given RM technology, nor that all RM technologies will be disruptive in exactly the same way.5 The ESRC-funded Biomodifying Technologies project6 analysed three case studies of biotechnologies with disruptive potential: gene-editing which allows faster, more accurate genetic modification, induced pluripotent stem cell (iPSC) technology that allows an ordinary skin or blood cell to be turned into a stem cell capable of producing any tissue type in the human body, and 3D bioprinting which can produce three-dimensional structures made from living tissues.

Gene editing and iPSC are advances on earlier generations of genetic engineering and stem cell technologies. They align reasonably well with the existing skill sets, goals, equipment, and techniques of researchers working in both academic and commercial settings. They are not especially disruptive at the level of basic research. Bioprinting requires skills, tools and techniques from engineering, materials chemistry, computer-aided design, biology, and medicine. This has necessitated greater disruption in the form of organisational change, to create new research groups and foster collaborative learning across disciplines.

For all three technologies, there are also well-established pathways to extract near-term value from basic research: peer-reviewed publications, patent applications, and the market for reagents, tools, and equipment. Each case demonstrates clear growth in the number of papers, patents, and reagent/equipment sales, although the rate of acceleration is greatest for CRISPR-based gene editing and slowest for bioprinting.

The pathways to realise longer-term, clinical, and economic value are less well established for RM. The healthcare sector is seen as particularly resistant to disruptive innovations, due to the lengthy regulatory process and powerful incumbent firms, which have historically been wary of investing in RM.7 The process of scaling laboratory protocols for cell or gene-based therapies into industrial procedures, taking products through clinical trials to establish safety and efficacy, and securing reimbursement, is every bit as experimental and involves as much learning by trial and error as exploratory laboratory research, but with much higher financial stakes. Interest from incumbents appears to be growing, as recent years have seen an increase in the number of cell or gene-based therapies reaching the market. However, there is no off the shelf manufacturing solution, as different RM products have different attributes: in the industry there is a popular idiom the product is the process. This means that the acceleration seen at the basic R&D stage does not unproblematically translate into speedy translation further down the pathway.

Rather, initial clinical applications of gene editing, iPSC and bioprinting are targeted at a more limited range of niche applications. The niches for each technology are shaped by a number of critical factors. Smaller tissues, such as the eye require fewer replacement cells or lower titres of gene editing vector, which are more manageable with current manufacturing capacity. The challenges of manufacturing at scale, combined with high anticipated costs, combine to make narrowly defined subsets of disease categories, with high unmet need, a preferred route for commercial development, especially where there is potential for a disruptive new product to demonstrate significant Quality of Life gains over the current standard of care.

Indications that draw on procedures, standards and requirements established for previous therapies are seen as less risky and thus promising clinical targets. Gene editing to treat thalassemia and other blood disorders builds on decades of clinical expertise with the bodys haematopoietic (blood-forming) system, gained by treating leukaemia patients. Even treatments that were not ultimately successful such as foetal stem cell transplants for Parkinsons disease (PD) can provide expertise with clinical trials and regulation to support a next-generation iPSC-based cell therapy for PD.

While the government has rightly been wary of picking winners, as particular niches for early clinical adoption of biomodifying technologies become apparent they may require specific, targeted support, to complement the broader support for the field already provided by polices described above. Innovations in related fields such as biomaterials and automation, potentially supported by the High Value Manufacturing Catapult, are likely to improve manufacturing capacity and speed over time. These innovations may be relatively incremental in the manufacturing phase but could have disruptive effects further down the value chain at the clinical delivery phase, as greater supply makes biomodifying RM therapies accessible to less tightly defined patient cohorts. The next policy challenge will be to provide targeted support for clinical delivery whilst avoiding lock-in to infrastructure or procedures that would inhibit the evolution of the field over time.

The research underpinning this piece was supported by the Economic and Social Research Council grant number ES/P002943/1 and the Leverhulme Trust grant number RPG-2017-330

References

1 Department for Business, Industry and Industrial strategy (2017) Industrial Strategy: building a Britain fit for the future. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/730048/industrial-strategy-white-paper-web-ready-a4-version.pdf

2 Department for Business, Industry and Industrial strategy (2018) Bioeconomy strategy: 2018 to 2030. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761856/181205_BEIS_Growing_the_Bioeconomy__Web_SP_.pdf

3 Open Access Government (2019) The promises and challenges of biomodifying technologies for the UK https://www.openaccessgovernment.org/biomodifying-technologies/68041/

4 Accelerated Access Review (AAR). (2016). Final Report: Review of Innovative Medicines and Medical Technologies. London: The Crown.

5 Joyce Tait & David Wield (2019) Policy support for disruptive innovation in the life sciences, Technology Analysis & Strategic Management, DOI: 10.1080/09537325.2019.1631449

6 Open Access Government (2019) The promises and challenges of biomodifying technologies for the UK https://www.openaccessgovernment.org/biomodifying-technologies/68041/

7 Joyce Tait & David Wield (2019) Policy support for disruptive innovation in the life sciences, Technology Analysis & Strategic Management, DOI: 10.1080/09537325.2019.1631449

Please note: This is a commercial profile

Editor's Recommended Articles

Continue reading here:
Targeted policy support for emerging biomedical innovations - Open Access Government

Skin Stem Cells Comments Off on Targeted policy support for emerging biomedical innovations – Open Access Government | June 16th, 2020

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--Jun 15, 2020--

AVITA Medical Limited ACN 058 466 523 ( Company ) is pleased to announce that shareholders today voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries ( Avita Group ) from Australia to the United States of America ( Scheme ), under which AVITA Therapeutics, Inc. ( Avita US ), a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

Voting results of Scheme Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the resolution to approve the Scheme (set out in the Notice of Scheme Meeting contained in Appendix F of the Scheme Booklet) was passed on a poll by the requisite majorities of shareholders.

The voting results of the Scheme Meeting are attached to this announcement.

The Scheme will not be effective unless and until:

The Second Court Hearing is scheduled to be held at 9.30am (AEST) on Monday, 22 June 2020. If the Court approves the Scheme, the Company expects to lodge the Court orders with ASIC on Tuesday, 23 June 2020.

The expected timetable for implementation of the Scheme is set out below:

Event

Indicative Date

Second Court Hearing

22 June 2020

Effective Date for the Scheme

Last day of trading of the Companys shares on the ASX

23 June 2020

Listing of Avita US on the ASX

Trading of Avita US Chess Depositary Interests ( CDIs ) commences on the ASX on a deferred settlement basis

24 June 2020

Record Date (for determining the entitlements of shareholders of the Company to Avita US shares or Avita US CDIs)

7.00pm (AEST) on 25 June 2020

Last day of trading of the Companys American Depositary Shares ( ADSs ) on NASDAQ

Last day of trading of Avita US CDIs on the ASX on a deferred settlement basis

29 June 2020

Implementation Date

The shares of the Company are transferred to Avita US and Avita US shares or Avita US CDIs are issued to eligible shareholders of the Company

29 June 2020

Listing of Avita US on NASDAQ

Trading of Avita US shares commences on NASDAQ

Promptly following the Implementation Date

Trading of Avita US CDIs commences on the ASX on a normal basis

30 June 2020

The above dates are indicative only and are subject to change. The Scheme remains subject to satisfaction or, where applicable, waiver of the conditions precedent to the Scheme (as set out in the Scheme Implementation Agreement).

Any changes to the above dates will be announced to the ASX and NASDAQ and via news release, and will also be notified on the Companys website ( http://www.avitamedical.com ).

Authorised for release by the Chief Financial Officer of AVITA Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device ( https://recellsystem.com/ ) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this announcement include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this announcement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this announcement. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this announcement speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

The following information is provided in accordance with section 251AA of the Corporations Act 2001 (Cth).

Resolution details

Instructions given to validly appointed proxies (as at proxy close)

Number of votes cast on the poll

Resolutionresult

Resolution

For

Against

Proxysdiscretion

Abstain

For

Against

Abstain*

Carried / notcarried

That pursuant to and in accordance with section 411 of the Corporations Act 2001 (Cth), the scheme of arrangement proposed between the Company and the holders of its ordinary shares, the terms of which are described in the Scheme Booklet, of which the notice convening this meeting forms part, is approved, and the Board is authorised to agree to such alterations or conditions as are thought fit by the Court and, subject to approval of the Scheme by the Court, to implement the Scheme with any such alterations or conditions.

916,721,976

97.19%

20,950,290

2.22%

5,588,418

0.59%

3,786,450

N/A

926,498,581

97.75%

21,357,290

2.25%

3,876,450

N/A

Carried

Number of shareholders voting on the poll

For

Against

Abstain*

1,345

89.73%

154

Here is the original post:
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Results of Scheme Meeting - Manchestertimes

Skin Stem Cells Comments Off on AVITA Medical Limited Proposed Redomiciliation to the United States of America – Results of Scheme Meeting – Manchestertimes | June 15th, 2020

In short: sometimes. As much as wed like to give you a straight answer, hair loss and regrowth (on any part of the body) is a tricky thing thats influenced by many factors. However, heres what we know about eyebrow hair.

First up, if you want to see what your full regrowth is, it takes time: Generally, 4-6 weeks is when you'll experience what most brow specialists refer to as a full regrowth, however, there are people who tend to see growth up to 8-10 weeks. Then there are those who see very nominal growth beyond. I've had certain clients who we've been patient with letting their brows grow in and over the course of a year they saw little bits come in very slowly that were small, brow expert Joey Healy tells us. The majority of your regrowth will be seen in 4-6 weeks, sometimes 8."

So if youve given your strands a good several weeks to do their thing, and you are still seeing gaps, thinner areas, or the like, are they gone forever? Unfortunately, maybe. Repeatedly pulling out hairvia wax or tweezersis hard on the follicle. Do this too much, and the follicle becomes damaged and dies. Once that happens, the hair will never be able to grow back.

"Brows can thin over time as we age, but oftentimes brows thin even more as a result of over-plucking or over-tweezing," board-certified dermatologist Whitney Bowe, M.D. has previously told mbg. "Plucking, tweezing, threading, and waxing all pull the hair from the root, and there's only so much trauma each root can take. Repeating these insults to our hair root over time increase the likelihood that some hairs will never regrow, as too much damage has been done to the base of the root where the stem cells live."

So this means if you've been shaping your brows months, years, or decadesthere might not be much you can really do to turn back the clock.

Most people are surprised to learn that their brows have real limitations of regrowth, especially if you've been shaping your brows for a long period of time, saysHealy. You might be surprised how wimpy the new growth is even after waiting 8-10 weeks so yes, there is value to seeing what their maximum capacity is, but letting them regrow does not mean they are going to be back to the natural brows of your youth or they are not going to return to the natural brows you had before you starting shaping them.

Another issue is scar tissue, notes Healy: Know that hair will not grow on a burn or a scar either. For example, if you had a brow piercing or trauma to the skin that created a scar, no amount of time is going to cover that because the hair follicle is compromised when the brow is scarred.

Read the original here:
Do Brows Grow Back? It Depends But Here's What You Can Do To Help - mindbodygreen.com

Skin Stem Cells Comments Off on Do Brows Grow Back? It Depends But Here’s What You Can Do To Help – mindbodygreen.com | June 15th, 2020

DetailsCategory: VaccinesPublished on Saturday, 13 June 2020 12:40Hits: 488

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years

In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression free at 18 months vs. 48% for comparators

LONDON, UK I June 12, 2020 I Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia.1,2,3

The results will be presented during the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress, 11 to 14 June 2020.

In the single-arm ACE-CL-001 trial, 86% of CLL patients treated with Calquence as a 1st-line monotherapy remained on treatment at a median follow up of more than four years. The trial showed an overall response rate of 97% (7% complete response; 90% partial response) and a 100% overall response rate in subgroups of patients with high-risk disease characteristics, including genomic aberrations (17p deletion and TP53 mutation), immunoglobulin mutation status (unmutated IGHV), and complex karyotype. Safety findings showed no new long-term issues.1,4

In the final analysis of ASCEND, an estimated 82% of patients with relapsed or refractory CLL treated with Calquence remained alive and free from disease progression at 18 months compared with 48% of patients on rituximab combined with idelalisib or bendamustine.2 The trial previously met the primary endpoint of Independent Review Committee-assessed progression-free survival at the interim analysis.5

Richard R. Furman, Director of the CLL Research Center, Weill Cornell Medicine said: These data demonstrate no new safety concerns for acalabrutinib, confirming its ability to safely provide meaningful, long-term clinical benefit for patients with treatment-naive and relapsed or refractory disease. The safety profile of acalabrutinib makes treatment to progression an important and plausible option for patients.

Jos Baselga, Executive Vice President, Oncology R&D said: These long-term data reaffirm that Calquence delivers a durable response with a favourable safety profile for chronic lymphocytic leukaemia patients. Patients with chronic lymphocytic leukaemia are typically 70 years or older with comorbidities and often require treatment over a long time, making the sustained safety and efficacy profile highly relevant to their quality of life.

Results from the Phase II ACE-CL-001 trial informed the development of the pivotal Phase III ELEVATE TN trial, which, along with findings from the Phase III ASCEND trial, formed the basis for the US approval of Calquence for the treatment of patients with CLL or small lymphocytic lymphoma (SLL).

Calquence in previously untreated CLL: 4.4-year follow-up from Phase II trial (abstract #S163)

The Phase II ACE-CL-001 trial investigated safety and efficacy of Calquence (100mg twice-daily [n=62] or 200mg once-daily [n=37]) in previously untreated patients with CLL.1 On 1 May 2015, patients receiving the 200mg dosing regimen were switched to the 100mg regimen.1

Key data from the Calquence Phase II ACE-CL-001 trial1

CI, confidence interval; CR, complete response; DoR, duration of response; EFS, event free survival; TTR, time to response; NR, not reached; ORR, overall response rate; PR, partial response

Response rates were 100% in each subgroup of patients with high-risk disease characteristics (unmutated IGHV [n=57], 17p deletion [n=9], TP53 mutation [n=9], and complex karyotype [n=12]), and reduction in lymph node disease was noted in all patients tested (n=97).1

At the time of data cut-off, 85 (86%) patients receiving Calquence remained on treatment. Six patients discontinued treatment due to adverse events (AEs) and three patients discontinued for progressive disease (PD). No patient discontinued Calquence due to bleeding events, hypertension, or atrial fibrillation. Incidence of AEs generally diminished with time on the trial. The most common AEs (40%) of any grade in the trial were diarrhoea (52%), headache (45%), upper respiratory tract infection (44%), arthralgia (42%), and contusion (42%). All-grade and Grade 3 events of clinical interest included infection (84% and 15%, respectively), bleeding events (66%, 3%), hypertension (22%, 11%), leukopenia (9%, 9%), and thrombocytopenia (3%, 1%). Atrial fibrillation (all grades) occurred in 5% of patients with Grade 3 occurring in 2%. Second primary malignancies (SPM) excluding non-melanoma skin (all grades) occurred in 11% of patients.1 Serious adverse events (SAEs) were reported in 38% of patients. SAEs occurring in more than two patients included pneumonia (n=4) and sepsis (n=3).1

Final results of Calquence Phase III ASCEND trial in relapsed or refractory CLL (abstract #S159)

ASCEND was a global, randomised, multicentre, open-label, Phase III trial that investigated the efficacy and safety of Calquence (100mg twice-daily) versus investigators choice of rituximab combined with idelalisib (IdR) or bendamustine (BR) in patients with relapsed or refractory CLL.2

Key data from the final analysis of the Calquence Phase III ASCEND trial2

BR, rituximab in combination with bendamustine; CI, confidence interval, DoR, duration of response; HR, hazard ratio; IdR, rituximab in combination with idelalisib; INV, investigator; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival

Sixteen per cent of patients on Calquence, 56% of patients on IdR, and 17% of patients on BR discontinued treatment because of AEs. Common AEs occurring in greater than 15% of patients of any grade in the Calquence arm of the trial included headache (22%), neutropenia (21%), diarrhoea (20%), upper respiratory tract infection (20%), cough (16%), and anaemia (16%). Events of clinical interest for Calquence versus controls included atrial fibrillation (all grade, 6% and 3%, respectively), major haemorrhage (all grade, 3% in both arms), infections (Grade 3, 20% and 25%, respectively), and SPM excluding non-melanoma skin cancer (all grade, 5% and 2%, respectively). SAEs (any grade) occurred in 33% of patients receiving Calquence, 56% of IdR patients, and 26% of BR patients.2

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is one of the most common types of leukaemia in adults, with an estimated 105,000 new cases globally in 2016 and 21,040 new cases in the US in 2020, and the number of people living with CLL is expected to grow with improved treatment as patients live longer with the disease.3,6,7,8 In CLL, too many blood stem cells in the bone marrow become abnormal lymphocytes and these abnormal cells have difficulty fighting infections.3 As the number of abnormal cells grows there is less room for healthy white blood cells, red blood cells, and platelets.3 This could result in anaemia, infection, and bleeding.3 B-cell receptor signalling through Brutons tyrosine kinase is one of the essential growth pathways for CLL.

Calquence

Calquence(acalabrutinib) is a next-generation, selective inhibitor of Brutons tyrosine kinase (BTK).Calquencebinds covalently to BTK, thereby inhibiting its activity.4,9 In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.4

Calquenceis approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in nine countries and for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy in 14 countries. The US MCL indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. As part of an extensive clinical development programme, AstraZeneca and Acerta Pharma are currently evaluatingCalquencein 23 company-sponsored clinical trials.Calquenceis being developed for the treatment of multiple B-cell blood cancers including CLL, MCL, diffuse large B-cell lymphoma, Waldenstrm macroglobulinaemia, follicular lymphoma, and other haematologic malignancies.

AstraZeneca in haematology

Leveraging its strength in oncology, AstraZeneca has established haematology as one of four key oncology disease areas of focus. The Companys haematology franchise includes two US FDA-approved medicines and a robust global development programme for a broad portfolio of potential blood cancer treatments. Acerta Pharma serves as AstraZenecas haematology research and development arm. AstraZeneca partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With six new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to AstraZeneca's main capabilities, the Company is actively pursuing innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by the investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms - Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visitastrazeneca.comand follow the Company on Twitter@AstraZeneca.

Media

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

1. Byrd JC, et al. Acalabrutinib in Treatment-Nave Chronic Lymphocytic Leukemia: Mature Results From Phase 2 Study Demonstrating Durable Remissions and Long-Term Tolerability. Abstract S163 presented at the Virtual Edition of the 15th European Hematology Association (EHA) Annual Meeting. Available online. Accessed June 2020.

2. Ghia P, et al. Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Abstract S159 presented at the Virtual Edition of the 15th European Hematology Association (EHA) Annual Meeting. Available online. Accessed June 2020.

3. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ)Patient Version. Available online. Accessed June 2020.

4.Calquence(acalabrutinib) [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; 2019.

5. Ghia P, et al. ASCEND Phase 3 Study of Acalabrutinib vs Investigators Choice of Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Abstract LB2606 at the 2019 European Hematology Association (EHA) Annual Meeting. Available online. Accessed June 2020.

6. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. JAMA Oncol. 2018;4(11):1553-1568.

7. American Cancer Society. Key Statistics for Chronic Lymphocytic Leukemia. Available online. Accessed June 2020.

8. Jain N, et al. Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies. Blood. 2015;126:871.

9. Wu J, Zhang M & Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.J Hematol Oncol. 2016;9(21).

SOURCE: AstraZeneca

Read the original here:
Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials | Vaccines | News Channels -...

Skin Stem Cells Comments Off on Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials | Vaccines | News Channels -… | June 14th, 2020

You can count the R&D execs at AbbVie among the believers in Genmabs bispecific platform tech.

Moving beyond the Allergan buyout, AbbVie refocused on its cancer drug pipeline, shelling out $750 million in cash and promising up to $3.15 billion more in milestones 60% for development and regulatory goals to ally itself on a slate of 7 development and discovery programs.

At the front of the queue is the early-stage drug epcoritamab, a CD3xCD20 bispecific from its DuoBody collection. Theres also DuoHexaBody-CD37 and DuoBody-CD3x5T4. And then AbbVie gets to pick and choose from among the discovery work at Genmab for 4 more, with AbbVie adding in its own contributions in the pairing up to come.

Unlock this story instantly and join 83,600+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the original here:
Sure, Bit Bio got some significant cash for its cell coding work. But it's the insiders who are backing them that will garner the attention -...

Skin Stem Cells Comments Off on Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention -… | June 14th, 2020

When Eoin OBrien found out he had a rare form of cancer, he was told he would have died within a week had he not gone to hospital.

Now, five years on, the dad of four is remarkably free of the disease.

Eoins life changed in May 2015 when he went to A&E with chest pains.

He was diagnosed with Hodgkins lymphoma, which causes abnormal growth of cells in the lymphatic system.

Due to fluid build-up, Eoins heart would have suffocated within days had he not been treated.

And after half a decade of pain and suffering, he is finally in remission.

The news came on his wife Karens birthday, making it all the more special for the pair and their daughters Sophie, 13, Abbie, 11, Maddie, eight, and three-year-old Emelie.

Karen said: To say that that was the best news ever would be an understatement, I would rather be told that 10 times over than even win the lotto.

Eoin was only 31 when he was diagnosed following a hospital visit after he started getting pains in his chest.

Doctors drained three-and-a-half litres of fluid from his chest and found a tumour between his lungs and heart.

After his first round of chemo didnt work, Eoin found a lump on his neck.

He was started on a higher dose of chemo which was, in his wife Karens opinion, the hardest one on him.

She explained: Eoin got the moon-face, he got the cancer look. Darkness under the skin of his eyes and that.

The pair hoped this treatment was working but were disappointed again when doctors told them it hadnt.

Two years later in 2017, when Karen was pregnant with Emelie, Eoin still wasnt responding to treatments.

He was due to go into hospital after his daughter was born for a planned stem cell transplant which was later cancelled.

The pair fought to get Eoin immunotherapy, which slowed down but didnt cure his cancer.

In 2019, he was told he could get an allogeneic stem cell transplant from a donor. Karen explained: So on the 6th of November, which we now class as Eoins re-birthday, he was given the transplant and he became so, so bad.

Eoin was at the stage where he wanted to give up. He didnt want to live anymore, he didnt want to go through it anymore.

Results of a scan in February had alarming results which left the two terrified the cancer had spread.

Thankfully, it was only an infection.

Eoin was hospitalised for six weeks and due to the coronavirus, wasnt allowed outside or to have visitors.

In May, the pair were given the news his transplant worked.

Karen said: Theres been a lot of ups and a lot of downs but were finally out the other side, so hopefully we can look forward to many, many years cancer-free.

Read more here:
Irish dad with rare form of cancer would have died within a week if he didn't go to hospital - Irish Mirror

Skin Stem Cells Comments Off on Irish dad with rare form of cancer would have died within a week if he didn’t go to hospital – Irish Mirror | June 14th, 2020

This was reprinted with permission from Joe Boggs, OSU

Poison hemlock (Conium maculatum) and wild parsnip (Pastinaca sativa) are two of our nastiest non-native weeds found in Ohio. Poison hemlock is one of the deadliest plants in North America. Wild parsnip can produce severe, painful blistering. Both are commonly found growing together.

Poison hemlock and wild parsnip are members of the carrot family, Apiaceae. The old name for the family was Umbelliferae which refers to the umbel flowers. They are a key family feature with short flower stalks rising from a common point like the ribs on an umbrella.

Poison hemlock produces white flowers on stalks that create a more rounded look; perhaps a bit more like an umbrella. Wild parsnip has intense yellow flowers with the stalks producing a more flat-topped appearance.

Both are biennial weeds meaning that it takes two years for plants to produce seed. The seeds currently being produced will give rise to plants that spend their first year as low-growing basal rosettes. The plants produce a long, thick taproot while in this stage.

During their second year, plants "bolt" by producing erect, towering stalks and multi-branched stems topped with umbel flowers. Mature wild parsnip plants may top 6' tall while poison hemlock plants can tower to as much as 8 - 10' tall. Both are prolific seed producers

Wild parsnip plants have leaves that look vaguely like celery, another member of the carrot family. Mature plants have a single, thick, deeply grooved, greenish-yellow stem that sprouts lateral branches topped with flowers.

All stages of poison hemlock plants have bluish-green leaves that are 3-4 times pinnately compound. The deeply cut parsley-like leaflets have sharp points. Flowering plants have hairless, light-green to bluish-green stems that are covered with obvious reddish-purple blotches. However, the blotches may occasionally coalesce to cause stems to appear an almost solid color.

What are the Risks?

Poison hemlock plants contain highly toxic piperidine alkaloid compounds which cause respiratory failure and death in mammals. The roots are more toxic than the leaves and stems; however, all parts of the plant including the seeds should be considered dangerous.

The toxins must be ingested or enter through the eyes or nasal passages to induce poisoning; they do not cause skin rashes or blistering. Regardless, this plant should not be handled because sap on the skin can be rubbed into the eyes or accidentally ingested while handling food.

Wild parsnip sap contains psoralen which presents a completely different mode of action compared to the piperidine alkaloids in poison hemlock sap. Psoralen acts as a photosensitizing compound by inhibiting DNA synthesis in epidermal cells which kills these light-shielding cells responsible for protecting us from long-wave ultraviolet radiation (LWUVR) bombarding us in sunlight.

Severe blistering occurs when affected skin is exposed to LWUVR. The synergistic effect is called phytophotodermatitis (a.k.a. Berloque dermatitis) and the burn-like symptoms, as well as skin discoloration, may last for several months.

However, connecting skin blistering to exposure to wild parsnip sap can be a challenge. It takes around 24 hours for symptoms to first appear after exposure to LWURV and severe blistering typically doesn't peak until 48 -72 hours. The time required for symptoms to appear after exposure to the sap means the effect may be disconnected from the cause.

Another challenge with connecting the dots is that wild parsnip commonly grows in and around other weeds, particularly poison hemlock (Conium maculatum). Gardeners who are exposed to wild parsnip sap while weeding a mixed-patch may mistakenly blame the poison hemlock for their ultimate misery.

To Mow, or Not to Mow

The potential for poisonings from poison hemlock sap and the extreme skin reaction to the wild parsnip sap means these non-native invasive weeds should not be allowed to grow where they can be easily contacted by people. However, mechanical control through mowing, weed trimming, or hand-pulling is problematic. Certainly, wild parsnip presents a much higher risk with reports of sap spattered by mowers and string trimmers producing phytophotodermatitis on exposed arms and legs of equipment operators.

Still, mowing provides one option for managing poison hemlock and to a lesser degree wild parsnip. However, timing is everything: plants should be mowed in the spring once they've bolted but prior to the appearance of flowers. Waiting until after flowering presents a risk the cut flowers will still mature to seed.

Chemical Control: Case Study

A strong case can be made for herbicides providing the most effective and safest approach to managing both poison hemlock and wild parsnip.

Wild parsnip and poison hemlock are both susceptible to non-selective post-emergent herbicides such as glyphosate (e.g. Roundup). However, "non-selective" means all plants - both good and bad - may be killed and there is a considerable downside to killing the competition as well as the targeted weeds.

Post-emergent herbicides do not affect seeds. Thus, "herbicidal openings" that occur when all plants are killed provide the perfect opportunity for more wild parsnip and/or poison hemlock to spring forth from previously deposited seed. Thus, it's important to have a plan for establishing competitive plants after the wild parsnip dies off such as over-seeding with grasses.

Selective post-emergent herbicides that will preserve competitive plants, particularly grasses, while removing poison hemlock and wild parsnip include 2, 4-D, clorpyralid (e.g. Transline), metsulfuron (e.g. Escort XP), and some 2 and 3-way products such as Triamine (2,4-D + MCPA). However, timing is equally important. Apply after the spring emergence of the targeted weeds but before flowering.

For more information, contact the Pulaski County Extension Service at 606-679-6361. Learn about timely events or things to do in your home gardens by becoming a fan of Pulaski County Horticulture on Facebook, or following @hortagentbeth on Twitter, kyplants on Instagram, and Pulaski County Horticulture YouTube channel.

The Pulaski Co Extension office is open to the public by appointment only through the month of June. Extension employees are still on the job and can be reached via office phone. Read the entire directive on the Pulaski County Cooperative Extension website at pulaski.ca.uky.edu.

The Lake Cumberland Master Gardeners are temporarily out of pine straw. Another load will be coming soon.

Educational programs of Kentucky Cooperative Extension serve all people regardless of economic or social status and will not discriminate on the basis of race, color, ethnic origin, national origin, creed, religion, political belief, sex, sexual orientation, gender identity, gender expression, pregnancy, marital status, genetic information, age, veteran status, or physical or mental disability.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Continue reading here:
Poison hemlock and wild parsnip, A couple of bad actors - Commonwealth Journal's History

Skin Stem Cells Comments Off on Poison hemlock and wild parsnip, A couple of bad actors – Commonwealth Journal’s History | June 14th, 2020

Vitamin C Face Serum Triple Strength Anti Aging, Wrinkle & Brightening Facial Care Antioxidant Rich, Hydrating, Softening & Even Skin Tone Treatment Made With Niacinamide & Glycolic Acid 1 oz Price, Features and Real Customers Reviews.

Check The Updated Price of Vitamin C Face Serum Triple Strength Anti Aging, Wrinkle & Brightening Facial Care Antioxidant Rich, Hydrating, Softening & Even Skin Tone Treatment Made With Niacinamide & Glycolic Acid 1 oz:

Price: Check Price on Amazon

Top Features of Vitamin C Face Serum Triple Strength Anti Aging, Wrinkle & Brightening Facial Care Antioxidant Rich, Hydrating, Softening & Even Skin Tone Treatment Made With Niacinamide & Glycolic Acid 1 oz Are:

3 POWERFUL FORMS OF VITAMIN C Our Triple Strength facial serum incorporates three powerful forms of Vitamin C to effectively address aging concerns within multiple layers of the skin, while reducing signs of aging. Our anti aging serum also leverages the power of Glycolic Acid to boost cell turnover and exfoliating dulling skin cells, allowing for enhanced absorption of the active ingredients into the skin.ANTI AGING FACE SERUM The 3 advanced forms of Vitamin C in our anti wrinkle serum effectively addresses aging concerns. Enhanced with Glycolic Acid, Niacinamide and NASA Stem Cell Technology, our hydrating serum targets the appearance of deep wrinkles while renewing, brightening and softening the skin for a smooth and even complexion.HEALTHIER SKIN COMPLEXION Our brightening serum defends against external aggressors, supporting overall skin barrier strength. This anti aging skin care treatment leverages Niacinamide and Glucosamine to support skin strength and improve moisture. These benefits further support a reduction in the look of wrinkles and improves radiance, while brightening the look of skin.PERFECT FOR ALL SKIN TYPES Our vitamin c facial serum works great for men, women and all skin types including normal, dry, oily or combination. Its great for naturally treating anti aging skin concerns, deep wrinkles and mature skin! On cleansed & toned skin, apply a dime sized amount of the serum in light, upward motions. For best results, we recommend applying at night & following with your favorite moisturizer. Daily application of an SPF is strongly encouraged while using this product.100% SATISFACTION GUARANTEE InstaNatural products are developed and manufactured in registered, GMP compliant facilities in the USA. Every product is free from parabens, sls/sles, mineral oil, formaldehyde releasers, synthetic dyes, petroleum, polyethylene glycol (PEGs), DEA/MEA/TEA, and unsafe preservatives. We are Leaping Bunny Certified meaning we do not test our products on animals at any stage in product development. Feel free to contact us with any questions or concerns.

Verified Customers Reviews of Vitamin C Face Serum Triple Strength Anti Aging, Wrinkle & Brightening Facial Care Antioxidant Rich, Hydrating, Softening & Even Skin Tone Treatment Made With Niacinamide & Glycolic Acid 1 oz:

See original here:
Vitamin C Face Serum - Triple Strength Anti Aging, Wrinkle & Brightening Facial Care - Antioxidant Rich, Hydrating, Softening & Even Skin Tone...

Skin Stem Cells Comments Off on Vitamin C Face Serum – Triple Strength Anti Aging, Wrinkle & Brightening Facial Care – Antioxidant Rich, Hydrating, Softening & Even Skin Tone… | June 14th, 2020

We are down to top nine of MasterChefAustralia 2020. That may seem like an odd point at which to call the winner. But hey, we're just that invested.

Below, I have compiled a list of whose unbalanced/under-seasoned/shallow-flavoured dish is going to send them home next; from Sunday night's all-in street-food elimination, right through to the finale.

No matter what happens on Masterchef, we'll always have Katy Perry. Relive the magic of her episode below. (Post continues.)

'Based on what?' I hear you ask.

Good question.

I could walk you through some highly advanced modelling based on past performance and predictive analytics, but I didn't actually do any of that.

Instead, I used a mix of womanly instinct, unashamed favouritism and a few spoilersfrom The Daily Mail.

So here we go. In a very particular order...

A forensic analysis of the promo for Sunday night's episode has led me to conclude that Khanh is going home next.

By which I mean they're setting it up to look like Emelia is going which means she definitely isn't, and there are lingering shots of Khanh, and the words 'fan favourite' are used.

AND the tabloids have reported that he doesn't make the top six... and... and... I just have a hunch.

Tessa is probably the most versatile cook in the joint.

Technically skilled, intuitive, knowledgeable. I don't anticipate a major stuff up sending her home.

She will likely only be felled by someone else pulling, as Andy would say, "a really cracking plate of food" out of their backside.

...will still be happy when he leaves, because he's Callum.

The mums of Australia, meanwhile, will be very sad because "he just seems like such a nice boy".

Sweet, Brendan. You are too good for reality television.

Run, run far away. (Preferably towards my house, say, around dinner time...)

This one will hurt most of all.

But at least we will get an uplifting montage of his best moments; like that time he hid beneath his bench when Katy Perry approached, and that time he won two challenges in a row and someone said, "It's Reece week" and he replied "Oh my god, it IS Reece week."

That was fun.

Excerpt from:
A definitive ranking of who will win MasterChef Australia 2020. - Mamamia

Skin Stem Cells Comments Off on A definitive ranking of who will win MasterChef Australia 2020. – Mamamia | June 13th, 2020

WHEN Tony Ferreira developed a small skin rash on his lower back - he assumed it would be gone in a few days.

And given the dad-of-one, 40, had always been fit and healthy, the last thing to cross his mind was that it could be cancer.

4

However, Tony's worst fears became a reality when the rash rapidly spread across his body - causing his feet and hands to split open.

Doctors soon diagnosed the gardener, from Jersey, with a rare form of non-Hodgkin lymphoma called Sezary syndrome - which has now affected about 90 per cent of his body.

Desperate to keep her husband alive, Tony's wife Osvalda is now pleading for a stem cell donor to come forward and save his life.

She said: "We pray that a stranger will help us to continue our lives together for many years to come."

We pray that a stranger will help us to continue our lives together for many years to come

Tony's nightmare first begun in 2012, when he noticed a small rash on his lower back which did not go away.

The rash quickly developed - causing his hands and feet would split open - and Tony then noticed lumps in his groin and under his arms.

Five years on, in 2017, medics diagnosed Tony, originally from Madeira, with a rare form of non-Hodgkin lymphoma called Sezary syndrome.

The condition causes white blood cells to become cancerous and aggressively attack the skin.

4

4

About 90 per cent of Tony's body is now affected by the rare cancer, and his best chance of survival is blood stem cell donation.

His wife is now desperately hoping a stem cell donor will come forward.

The charity DKMS is co-ordinating the worldwide search for a donor, but Tony's Portuguese heritage is making it much more difficult for him to find a match.

Tony's parents and four siblings have been checked as a potential match, but none are suitable.

In March, Tony's doctors decided to treat him with a new anti-cancer chemotherapy drug (mogamulizumab) but the trial was then delayed due to the Covid-19 pandemic.

Osvalda, who worked as a housekeeper for a care home in Jersey, had been keeping the family afloat financially, but was then advised to take temporary leave due to the risk she might contract Covid-19 and pass it on to her husband.

She said: "Tony's condition is bad enough, but for thousands of patients living with cancer in the UK, Covid-19 has delayed many treatments.

"We're not sure yet when we can begin travelling to London for treatment or what the new normal will look like.

"I long to hold Tony's hands again, without his protective gloves on.

4

What is Sezary syndrome?

Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin.

It is characterised by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes.

Although Sezary syndrome can affect people of all ages, it is most commonly diagnosed in adults over age 60.

The signs and symptoms of this condition can vary but may include:

Affected people may also have an increased risk of developing anotherlymphomaor other type ofcancer.

The exact cause of Sezary syndrome is currently unknown.

Source: Rare Diseases

Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

"Tony has been wearing his blue plastic gloves so long now that I've almost forgotten how his hands feel without them.

"He has such strong hands and holding them would reassure me that everything is going to be all right."

Jonathan Pearce, chief executive officer at DKMS UK, said the charity had seen a 50 per cent drop in the number of people coming forward to be donors due to coronavirus.

He added: "We are hugely concerned about the impact Covid-19 is having on those who rely on a blood stem cell donor.

"While many stem cell transplants are still going ahead, the logistics around supporting blood stem cell donors to travel to hospital, and then arranging the transport of the stem cells to the transplant centre, have become much more challenging and complex.

BIZ HOPEPubs & shops could ignore 2m distance rule if they take steps to lower virus risk

WAR IN THE STREETThugs batter each other with poles and cricket bats in mass street brawl

Breaking

PARTY SHOOTINGTwo women shot and man fighting for life after gunmen opened fire at party

'COP ATTACK'Three men in court charged with attacking cops - as boy, 13, admits assault

Exclusive

BOUNCE BACK BRITONDad who beat virus after record 65 DAYS on ventilator leaves hospital

RACE ROWFawlty Towers 'don't mention war' episode to be REINSTATED after Cleese waded in

"There are also transplants that have been delayed, but once the pandemic is over we know there will be a backlog of patients in urgent need of an unrelated blood stem cell donor.

"Sadly though, in some of those cases there's a risk that the disease could progress further, and a transplant may no longer be possible once this is all over."

People can register for a swab kit here.

Here is the original post:
I thought it was just a rash but rare cancer now covers 90% of my skin splitting my hands and feet open - The Sun

Skin Stem Cells Comments Off on I thought it was just a rash but rare cancer now covers 90% of my skin splitting my hands and feet open – The Sun | June 13th, 2020

Global Exosome Therapeutic Market report is of huge importance when it is about building business strategy by identifying the high growth and attractive market categories. This report assists to design capital investment strategies based on forecasted high potential segments. With this market report, it becomes simple and easy to develop competitive strategy based on competitive landscape. Moreover, potential business partners, acquisition targets and business buyers can be identified by using this Exosome Therapeutic Market research report. To plan for a new product launch and inventory in advance, this business report provides several useful insights.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

See original here:
Exosome Therapeutic Market 2020 Analysis, Trends, Opportunity, Size And Segment | Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE...

Skin Stem Cells Comments Off on Exosome Therapeutic Market 2020 Analysis, Trends, Opportunity, Size And Segment | Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE… | June 13th, 2020

A new finding in South Korea reveals that the ancestors to the modern crocodile walked on two legs. The 106-million-year-old fossilized foot impressions of the crocodylomorph suggest that the ancient reptile was 2 to 3 meters long, as the researchers published in the journal Scientific Reports.

Professor Kyung Soo Kim and his team from the Chinju National University of Education found the footprints and skin traces at the Sacheon Jahye-ri site of theJinju Formation. The team was able to conclude that the creatures must have been bi-pedal, as there were no hand impressions or front feet impressions present at the site.

The footprints were initially thought to be made by a giant bipedal pterosaur walking on the mudflat, we now understand that these were bipedal crocodile prints, said University of Queenslands Dr. Anthony Romilio. The footprints measure around 21 cm, suggesting the track-makers had legs about the same height as human adult legs. These were long animals that we estimate were over 3 m in length. Source: Sci News.

Read Also: Human embryo model grown from stem cells by scientists for the first time

The newly found tracks were named Batrachopus grandis, in comparison to the smaller Batrachopus type tracks.

Previous discoveries have also hinted that ancient crocodiles could have been bi-pedal. One example was the skeletal reconstructions ofCarnufex carolinensis, an ancient croc that walked 231 million years ago, according to Science News. However, these footprints are concrete proof that ancient crocodiles used to walk on two limbs.

These types of findings are crucial in learning about past life on our planet, even helping us better interpret other dinosaur fossils.

Do you want to publish on Apple News, Google News, and more?Join our writing community,improve your writing skills, and be read by hundreds of thousands around the world!

View original post here:
Ancient crocodiles used to walk on two feet, new footprints reveal - News Landed

Skin Stem Cells Comments Off on Ancient crocodiles used to walk on two feet, new footprints reveal – News Landed | June 13th, 2020

Global Exosome Therapeutic Market report is of huge importance when it is about building business strategy by identifying the high growth and attractive market categories. This report assists to design capital investment strategies based on forecasted high potential segments. With this market report, it becomes simple and easy to develop competitive strategy based on competitive landscape. Moreover, potential business partners, acquisition targets and business buyers can be identified by using this Exosome Therapeutic Market research report. To plan for a new product launch and inventory in advance, this business report provides several useful insights.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Go here to see the original:
Exosome Therapeutic Market 2020 to Show Tremendous Growth | Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United...

Skin Stem Cells Comments Off on Exosome Therapeutic Market 2020 to Show Tremendous Growth | Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United… | June 13th, 2020

Noveome Biotherapeutics is a clinical-stage company focused on developing therapies for the regenerative repair of tissues. Their product ST266, a first-of-its-kind, multi-targeted, non-cellular platform biologic comprised of a complex mixture of biomolecules, is currently being evaluated as a potential treatment for the severe inflammatory response observed in the lungs of some COVID-19 patients.Technology Networks recently spoke with William J. Golden, Noveome Biotherapeutics Founder, Chairman and CEO, who explains the underlying basis for investigating ST266s potential against COVID-19. Golden also elaborates on many of the other indications for which ST266 is being developed to treat.Laura Lansdowne (LL): Could you provide our readers with a brief overview of Noveome Biotherapeutics?William J. Golden (WJG): Noveome is a clinical-stage biotherapeutics company located in Pittsburgh, PA. The company was founded in 2000 by Bill Golden and Lancet Capital. The group was interested in exploring non-embryonic stem cells and identified a technology at the University of Pittsburgh that was using cells derived from human amnion, a membrane that closely covers the fetus during development. The company, named Kytaron Technologies, Inc. at the time, licensed that amnion cell technology but, ultimately, Noveome scientists were able to discover, develop and patent their own unique population of cells, called Amnion-derived Multipotential Progenitor (AMP) cells, using a proprietary culture method that follows current Good Manufacturing Practice (cGMP) regulations. These novel cells were used to produce our product, ST266.LL: What is ST266? Could you elaborate on its mechanism of action in relation to the healing process?WJG: Noveomes product, ST266, is the secretome produced by the AMP cells. It is a completely cell-free solution and is comprised of hundreds of biologically active molecules, including cytokines and growth factors. Interestingly, these cytokines and growth factors exist at very low physiological levels ranging from pg/mL ng/mL concentrations.1 The fact that such low concentrations of these molecules are biologically active is quite remarkable when you consider that traditional protein-based therapies are usually administered at concentrations that are orders of magnitude greater than the concentrations found in ST266.Because the composition of ST266 is so complex, its multiple mechanisms of action have only been partially elucidated. Clinical and preclinical studies have shown ST266 to be anti-inflammatory,2,3 promote wound healing,4,5 reduce apoptosis, reduce vascular permeability (manuscript in preparation), and restore cellular homeostasis.3 Preclinical studies have also shown ST266 to be neuroprotective. In a traumatic brain injury model, ST266 significantly protected against reactive gliosis, suggesting potent anti-inflammatory activity, and resulted in significant recovery of rotarod motor function.6,7 In another study, ST266 was tested in the experimental autoimmune encephalopathy (EAE) mouse model of multiple sclerosis (MS). In this model, the mice develop optic neuritis, which is among the presenting symptoms of MS in humans. ST266 was administered to the nares of mice 15 or 22 days after disease induction. ST266 is absorbed via capillary action along the olfactory nerves which bypasses the blood-brain barrier. This unique route of administration allows for the delivery of high molecular weight biologics to the optic nerve of the eye and the central nervous system. ST266 attenuated visual dysfunction, prevented retinal ganglion cell (RGC) loss, reduced inflammation, and decreased the rate of demyelination of the optic nerve in EAE mice.3Mechanistically, ST266 simultaneously acts on multiple cell receptor-activated and intracellular signaling pathways. For example, in the EAE MS model, neuroprotective effects involved oxidative stress reduction, SIRT1-mediated mitochondrial function promotion, and pAKT signaling.3 In a Phase 2 UV light burn study, ST266 reduced erythema and DNA damage and increased the expression of XPA DNA repair proteins.2Importantly, ST266 has a proven clinical safety profile. It has been administered to 243 patients by various routes of administration (topical skin, topical ocular, topical oral, targeted intranasal), and no drug-related serious adverse events have been reported. Preclinical studies of systemically administered ST266 have also yielded no drug-related safety concerns.LL: For what indications is ST266 currently being evaluated as a treatment?WJG: We refer to ST266 as a platform biologic. By this, we mean that ST266 is one product that has the potential to treat numerous and varied diseases. In the clinic, we have shown anti-inflammatory activity when ST266 is applied topically to UV light-burned the skin2 and topical application to the gums of patients with gingivitis and periodontitis showed a reduction in proinflammatory cytokines in the patients crevicular fluid (manuscript in preparation). We are currently conducting a Phase 2 open label trial of ST266 to treat persistent corneal epithelial defects (PEDs) when applied topically to the eye. Results from this trial will be published soon. We are currently planning a Phase 2b multi-center, randomized, double-masked trial to further evaluate the safety and efficacy of ST266 in this indication. Finally, we are conducting a Phase 1 study in patients at risk for developing glaucoma. This study is using the intranasal route of delivery described above in combination with a novel delivery device. The goal is to deliver ST266 directly to the optic nerve, where it can protect the RGCs that are damaged in glaucoma. We envision this route of delivery will be applicable to central nervous system and other back-of-the eye indications.We also have several ongoing preclinical programs that are evaluating systemically administered ST266 for more generalized inflammatory conditions. These data are not yet published but combined with the data we have compiled in preclinical and clinical studies of topical skin, topical oral and topical ocular administration, we believe ST266 has the potential to be an effective therapy for numerous systemic inflammatory conditions.LL: Could you elaborate on the underlying basis for your evaluation of ST266 as a potential treatment for COVID-19?WJG: As you know, a major complication of COVID-19 is the severe inflammatory response seen in the lungs of some patients. This response is called cytokine storm or cytokine release syndrome. As the pandemic continues and more data have become available, it is now known that the cytokine storm does not just affect the lungs. Multi-organ damage occurs in many of these patients. We believe that systemic delivery of ST266 and its anti-inflammatory activity has the potential to calm the storm. Our as-yet-unpublished preclinical studies with intravenous ST266 support this hypothesis and we are moving rapidly to initiate intravenous ST266 in a Phase 1 study. Once safety in humans is established by this route of administration, we will commence Phase 2 studies in COVID-19 patients.William J. Golden was speaking to Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.References

1. Steed, DL, C Trumpower, D Duffy, C Smith, V Marshall, R Rupp, and M Robson. (2008). Amnion-Derived Cellular Cytokine Solution: A Physiological Combination of Cytokines for Wound Healing. Eplasty 8: 15765.

2. Guan, Linna, Amanda Suggs, Emily Galan, Minh Lam, and Elma D. Baron. (2017). Topical Application of ST266 Reduces UV-Induced Skin Damage. Clinical, Cosmetic and Investigational Dermatology. DOI: https://doi.org/10.2147/CCID.S147112.

3. Khan, Reas S, Kimberly Dine, Bailey Bauman, Michael Lorentsen, Lisa Lin, Helayna Brown, Leah R Hanson, et al. (2017). Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model. Scientific Reports. DOI: https://doi.org/10.1038/srep41768.

4. Bergmann, Juri, Florian Hackl, Taro Koyama, Pejman Aflaki, Charlotte a Smith, Martin C Robson, and Elof Eriksson. (2009). The Effect of Amnion-Derived Cellular Cytokine Solution on the Epithelialization of Partial-Thickness Donor Site Wounds in Normal and Streptozotocin-Induced Diabetic Swine. Eplasty 9: e49.

5. Franz, Michael G, Wyatt G Payne, Liyu Xing, D K Naidu, R E Salas, Vivienne S Marshall, C J Trumpower, Charlotte A Smith, David L Steed, and M C Robson. (2008). The Use of Amnion-Derived Cellular Cytokine Solution to Improve Healing in Acute and Chronic Wound Models. Eplasty 8: e21.

6. Deng-Bryant, Ying, Zhiyong Chen, Christopher van der Merwe, Zhilin Liao, Jitendra R Dave, Randall Rupp, Deborah a Shear, and Frank C Tortella. (2012). Long-Term Administration of Amnion-Derived Cellular Cytokine Suspension Promotes Functional Recovery in a Model of Penetrating Ballistic-like Brain Injury. The Journal of Trauma and Acute Care Surgery DOI: https://doi.org/10.1097/TA.0b013e3182625f5f.

7. Deng-Bryant, Ying, Ryan D. Readnower, Lai Yee Leung, Tracy L. Cunningham, Deborah A. Shear, and Frank C. Tortella. (2015). Treatment with Amnion-Derived Cellular Cytokine Solution (ACCS) Induces Persistent Motor Improvement and Ameliorates Neuroinflammation in a Rat Model of Penetrating Ballistic-like Brain Injury. Restorative Neurology and Neuroscience. DOI: https://doi.org/10.3233/RNN-140455.

More here:
Exploring the Therapeutic Potential of ST266 Against Numerous Diseases Including COVID-19 - Technology Networks

Skin Stem Cells Comments Off on Exploring the Therapeutic Potential of ST266 Against Numerous Diseases Including COVID-19 – Technology Networks | June 12th, 2020

The light, non-greasy, dermatologically tested formula contains Vitamin B3 to help hydrate and support the skin barrier, and SPF30 for added sun protection. It alsosits beautifully under your regular SPF you'll have on, and makeup.

It won't clog your pores and doesn't include common irritants like fragrance or colour. The no-fuss formula also won't mess with the rest of your skincare, making it the easy to slot into your existing routine. Done!

(*Side note:Always read the label. Follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.)

Anyone else get dry lips in winter? This lip balm is brilliant for a few reasons.

A) It's super affordable and accessible - you'll find it at most pharmacies.

B) It has SPF50+ broad spectrum protection.

C) The texture isn't too thick or too thin, it's just right.

And D) You can wear the clear formula over the top of alip stain or lip liner.

Just don't leave it in the car, OK?

(And yes, you know the drill:Always read the label. Follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.)

See the article here:
'I found these 4 affordable winter skin saviours in the chemist beauty aisles.' - Mamamia

Skin Stem Cells Comments Off on ‘I found these 4 affordable winter skin saviours in the chemist beauty aisles.’ – Mamamia | June 12th, 2020

Dr. Rebecca Morris, leader of the Stem Cells and Cancer lab at The Hormel Institute, received a multi-year grant to study stem cells originating in adult bone marrow and their possible effects on skin diseases, including cancer. The grant, from the Nation Institute of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), awarded Morris with $373,688 over two years for her research project Identification of Novel Epidermal Progenitors.

Morris said this research is significant because it will contribute new understanding of epithelial biology, and blood and bone marrow in general, provide possible new targets for epithelial cancer prevention and control, validate liquid biopsy of blood as a diagnostic tool, and help her and her team to achieve their goal of preventing and alleviating chronic skin diseases including cancer, psoriasis, and epidermolysis bullosa.

Many years ago, I contributed basic research on identification and isolation of adult tissue stem cells from skin epidermis, and demonstrated their role in skin cancer initiation and promotion, Morris said. Now, I am again thrilled to be on the edge of discovery of a new population of epithelial stem cells and have the opportunity to determine their roles in regeneration and cancer.

Cells in the body that cover surfaces (like the epidermis, or top layer of skin) or line spaces (like ducts in mammary gland or lining of the colon) are called epithelial cells. In adults, most cancers originate from these epithelial cells. However, new research has identified certain bone marrow derived epithelial cells (BMDECs) in normal, healthy human subjects.

Morris and her team do not believe anyone has yet described the features and nature of these cells, or analyzed their function.

The research team has hypothesized that the epithelial cells from the bone marrow are epithelial stem cells. They therefore hope to demonstrate that BMDECs include a novel population of adult tissue stem cells that can be gathered to chronically compromised epithelium, such as skin cancer or psoriasis, and regenerate it.

Skin cancer is by far the most common type of cancer in the United States, with millions of people diagnosed each year. As we enter summer, it is important to remember simple steps like staying out of the sun during the middle of the day, staying in the shade, and wearing sunscreen can help reduce your skin cancer risk.

Next steps for Morriss research include determining how these blood borne epithelial cells are recruited to the skin, the recruiting molecules, how the recruitment can be good or bad, and how to modulate their recruitment to alleviate disease.

Follow this link:
Major skin cancer research study to begin at The Hormel Institute - Austin Daily Herald - Austin Herald

Skin Stem Cells Comments Off on Major skin cancer research study to begin at The Hormel Institute – Austin Daily Herald – Austin Herald | June 10th, 2020

(LOS ANGELES) -- Mesenchymal stem cells (MSCs) are multipotent in that they naturally replenish the cell types that build our bone, cartilage and adipose tissues. However, their much broader regenerative potential, based on their capacity to migrate and engraft in injured tissues and secrete factors that enhance the formation of new blood vessels, suppress inflammation and cell death, and promote healing, makes them exquisite candidates for cell-based therapies for diseases as varied as cardiovascular, liver, bone and cartilage diseases, lung and spinal cord injuries, autoimmune diseases and even cancer and skin lesions.

MSCs provoke no or negligible adverse reactions in patients that receive them from healthy donors, and can be easily isolated from human tissues, expanded to clinical scales, biopreserved, and stored for point-of-care delivery. This efficiency in preparing medical grade MSCs contrasts with the relative inefficiency with which they currently can be delivered to target tissues in patients. Clinicians often need to administer massive numbers of MSCs with high precision to reach sufficient numbers of cells that successfully engraft and remain functional over time.

To overcome this bottleneck, researchers have developed materials-based approaches in which MSCs are embedded in biomaterial scaffolds that then can be implanted as "patches" in minimally invasive procedures into damaged tissues. However, those cells are often limited in their ability to migrate, overcome tissue barriers, and successfully engraft in tissue microenvironments where their action is needed most. In principle, injection approaches can introduce MSCs into tissues via hypodermic needles in a more targeted manner, but any direct injection to the tissue is invasive and can cause inadvertent tissue damage and side effects like the formation of scar tissue.

Now, a new study reported in Advanced Functional Materials by a team at the Terasaki Institute for Biomedical Innovation in Los Angeles and the University of California, Los Angeles (UCLA) has developed a minimally invasive approach, which deploys "microneedles" that provide a bioactive depot of MSCs. By embedding comparatively low numbers of MSCs in a gel-like material that prolongs their viability and functionality, and targeting damaged tissues with high spatial precision, the researchers showed their approach to accelerate wound healing in a mouse model with excised skin segments.

"Microneedles have been successfully used in the past to painlessly deliver drugs to target tissues such as skin, blood vessels and eyes. We demonstrate here with 'Detachable Microneedle Depots' that an analogous approach can deploy therapeutic cells at target sites," said co-corresponding author Ali Khademhosseini, the Director and CEO of the Terasaki Institute who was previously Director of the UCLA Center for Minimally Invasive Therapeutics. "To achieve this, we developed an entirely new microneedle patch that supports stem cells' viability, responsiveness to wound stimuli, and ability to accelerate wound healing."

At the beginning of their study, Khademhosseini and his co-workers hypothesized that embedding MSCs in a biocompatible and biodegradable biomaterial matrix could help create a hydrated environment with the mechanical properties that stem cells need in order to remain alive and functioning over a longer time. The researchers started by engineering a matrix of gelatin fibers that are cross-linked to each other into a network that could accommodate MSCs. The biomaterial mimicked the normal extracellular environment of tissues that MSCs normally reside in, and it helped to remodel the specific matrix environment in a way that allowed MSCs to take up nutrients and communicate with damaged tissue via soluble factors that they normally receive and dispatch.

The other part of the challenge was to introduce the literal "needle" quality into the cell-delivering device that would enable it to gently penetrate tissues in order to reach their target sites. To this aim, the researcher encased the softer MSC-containing gelatin matrix with a second, much harder biomaterial known as poly(lactic-co-glycolic)acid, in short PLGA. Once the needles were brought into place in a wound bed, the "PLGA shell", which also is biocompatible and biodegradable, slowly degraded, but during the process kept the MSC-containing gelatin matrix in place, allowing MSCs to release their therapeutic factors through emerging gaps in the shell into the damaged tissue. The team showed that in the composite microneedle 90% of MSCs were kept viable for 24 hours, and that, importantly the cells did not lose their potential as stem cells ("stemness"), which was critical for their healing properties.

Finally, the team set out to investigate their microneedle concept in a mouse skin wound model in which a defined excision is made in the epidermal tissue layers. To be able to strategically place individual microneedles within the wound bed, a simple and effective deployment mechanism was devised by attaching an array of microneedles on a small strip of scotch tape with their pointy ends facing away from the tape. Precisely positioning the tape with its patterned microneedle surface on the wound, allowed the individual microneedles to penetrate into the wound bed. Then, the tape was peeled off, causing the microneedles to detach and remain embedded in the wound tissue. Khademhosseini and his co-workers summarized the device's salient features by naming it: "Detachable Hybrid Microneedle Depot" (d-HMND).

In the mouse model, the MSC-loaded d-HMND device indeed stimulated a number of critical parameters associated with wound healing. Compared to an equal number of MSCs injected directly into wounded skin, and a version of the d-HMND device that did not contain any MSCs (cell-free), the MSC-containing d-HMND accelerated the contraction of the wound and re-growth of the epidermal skin layers (re-epithelialization). The researchers used a panel of histological and molecular markers to confirm over a period of 14 days that the device suppressed inflammation, and stimulated tissue remodeling, the formation of new blood vessels, and re-growth of hair - all vital signs of a robust wound healing response.

"In future scenarios, d-HMNDs could be rapidly fabricated in clinical laboratories shortly before use, applied to treat skin injuries, and explored more broadly as treatments for a variety of other disorders, including melanoma and other dermatological disorders that could benefit from the power of MSC cells," said Khademhosseini. "The concept would even be compatible with using patient-derived cells in more personalized device approaches." Khademhosseini and his colleagues are exploring further uses of this technology as part of the Terasaki Institute's research program.

Go here to read the rest:
Microneedling therapeutic stem cells into damaged tissues - Science Codex

Skin Stem Cells Comments Off on Microneedling therapeutic stem cells into damaged tissues – Science Codex | June 10th, 2020

Recently, I have been impressed by the unlikely efficacy of pressure tools such as the Pause Fascia StimulatingTool ($115 in the shop) and the KNESKO Quartz Roller and mask set ($115 in the shop). I say unlikely because these tools have no underlying technology and require only a little pressure as you move them over the skin. They really appear to firm and rejuvenate, but there was no research to back this up. Until now.

I was super excited to come across some research conducted by beauty giant, Shiseido and Jichi University in Japan. Their studies revealed that the application of pressure to the skin stimulates the proliferation of stem cells and ultimately boosts collagen.

The research noted that stem cells are more prolific near the sebaceous glands in the skin and dubbed these stem cell reservoirs. When they applied pressure to the skin, the stem cells in the reservoirs proliferated. And not just by a few, the number of stem cells was increased significantly.

Thats all well and good, but does an increased number of stem cells result in better and/or younger looking skin? So the team then investigated whether the cells proliferated by pressure would function in the dermal layer.

For dermal cells to function properly, they need to connect to each other and reconstruct a network. When the researchers observed the cells in pressurized skin, they did indeed connect to each other and they reconstructed a network.

And the really good news is that cells that have reconstructed a network produce collagen. The the production of collagen allows the dermis to regain its elasticity and firmness.

So now we have it, tools that allow us to apply gentle pressure to our skin are helping us stimulate collagen production.

Become a member to read this article in full

Your membership includes:

Read the original:
Pressure Tools Boost Collagen - Truth In Aging

Skin Stem Cells Comments Off on Pressure Tools Boost Collagen – Truth In Aging | June 10th, 2020